http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Becton Dickinson (BDX) Granted 510(k) Clearance of Artificial Intelligence Software for MRSA Diagnostics
-
BD Gains 510(k) Clearance of Artificial Intelligence Software for MRSA Diagnostics
-
Health Care Collaboration in Denmark Aims to Reduce Medical Waste
-
BD Reports Second Quarter Fiscal 2023 Financial Results
-
BD Recognized by DiversityInc as a Top U.S. Company for Diversity in 2023 List
-
BD to Present at Bank of America Securities 2023 Health Care Conference
-
BD Board Declares Dividend
-
BD Recognized by Forbes as a Best Employer for Diversity in 2023 List
-
New Harris Poll Finds Women Want More Education on Sexually Transmitted Infections Testing and Treatment
-
BD Introduces Advanced Ultrasound Technology to Help Drive First-Stick Success for IV Insertions
-
BD to Announce Financial Results for its Second Quarter of Fiscal 2023
-
Michelle Quinn Named General Counsel for BD
-
Becton Dickinson (BDX) receives FDA 510(k) clearance for BD Vaginal Panel
-
BD Receives FDA 510(k) Clearance for First-of-Its-Kind High-Throughput Diagnostic Test for Infectious Vaginitis
-
BD to Present at Barclays Global Healthcare Conference
-
BD to Present at Cowen 43rd Annual Healthcare Conference
-
Becton Dickinson (BDX) Announces FDA Approval of BD Onclarity HPV Assay
-
BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test
-
BD Named as One of America's Best Large Employers
-
BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test
-
Becton Dickinson (BDX) Introduces High-Throughput Single-Cell Multiomics Platform
-
BD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery
-
BD Reports First Quarter Fiscal 2023 Financial Results
-
BD Named to Bloomberg Gender-Equality Index for 4th Consecutive Year
-
BD Publishes 2022 Cybersecurity Annual Report
-
BD Board Declares Dividend
-
BD Introduces Fully Automated Robotic Track System for Microbiology Labs
-
Becton Dickinson (BDX) and CerTest Granted FDA Emergency Use Authorization for Mpox Diagnostic Test
-
BD, CerTest Biotec Announce Emergency Use Authorization for Mpox Diagnostic Test
-
BD Announces Webcast of Annual Meeting of Shareholders
-
Michelle Quinn Named Acting General Counsel for BD
-
BD to Announce Financial Results for its First Quarter of Fiscal 2023
-
New Harris Poll Reveals Significant Gaps in Women's Knowledge About Cervical Cancer
-
BD to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
BD Releases 2022 Global Inclusion, Diversity and Equity Annual Report
-
BD Named in top 25% of Newsweek's 2023 List of America's Most Responsible Companies
-
BD to Present at Evercore ISI 5th Annual HealthCONx Conference
-
BD Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results
-
BD Board Increases Dividend for 51st Consecutive Year
-
BD, Magnolia Medical Technologies Announce Commercial Collaboration to Help Reduce Blood Culture Contamination and Improve Testing Accuracy
-
BD, BIOCORP Sign Agreement to Bring Connectivity, Traceability to Self-Administered Injectable Drugs
-
BD TO ANNOUNCE FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
-
BD Recognized Among World's Best Employers by Forbes
-
BD, Heart to Heart International, NAFC and Henry Schein Cares Award Critical Lab Equipment to Six U.S. Free and Charitable Clinics
-
BD Launches State-of-the-Art Cloud Software Solution to Streamline Flow Cytometry Research
-
Becton Dickinson (BDX) and CerTest Announce US Launch of Monkeypox Assay
-
BD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay
-
LivaNova Board Appoints Brooke Story as a New Director
-
Becton Dickinson (BDX) Launches Next Generation Prefillable Vaccine Syringe
-
BD Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

